Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Bacardi $1 billion notes offering
The investment-grade notes are due 2030 and 2035
Sanrio ¥135.1 billion secondary offering
The shares are listed on the Tokyo Stock Exchange
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Province of Saskatchewan $1 billion global bond offering
The investment-grade debt is due 2030
Bank of America $10 billion floating-rate and fixed-to-floating-rate notes
The five-tranche investment-grade debt offering is based on the Secured Overnight Financing Rate
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S…
PAR Technology $115 million convertible senior notes offering
The notes are due 2030
Central American Bank for Economic Integration $1.5 billion notes
The notes are due 2028
Emera exchange offer
We advised Emera on its exchange offer
Circle strategic commercial alliance with Binance to expand global USDC adoption
We advised Circle in entering into a unique strategic commercial arrangement with Binance to accelerate global USDC adoption